Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (171-180 of 244) with videos related to

Pageof 25
Sort By:
EJNMMI Research|March 17, 2025
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphomaMichael Beck, Viktoria Blumenberg, Veit L Bücklein, et al.
Clinical & Translational Immunology|March 11, 2020
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trialFelix S Lichtenegger, Frauke M Schnorfeil, Maurine Rothe, et al.
Hemasphere|April 11, 2023
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHLKai Rejeski, Viktoria Blumenberg, Gloria Iacoboni, et al.
Blood|February 26, 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyJoshua F Zeidner, David A Sallman, Christian Récher, et al.
Blood Advances|February 24, 2025
Gastrointestinal toxicity of Gemtuzumab Ozogamicin: Real-life data from the AMLCG, SAL and CELL study groupsRicarda Knabe, Philippe Muller, Christoph Schliemann, et al.
Transplantation|May 15, 2018
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsHeiner Zimmermann, Nina Babel, Daan Dierickx, et al.
Blood|July 25, 2022
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervalsNora Philipp, Maryam Kazerani, Alyssa Nicholls, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.
Leukemia|April 2, 2020
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemiaTobias Herold, Maja Rothenberg-Thurley, Victoria V Grunwald, et al.
Leukemia|August 2, 2024
Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemiaDaniel Atar, Lara Ruoff, Anna-Sophia Mast, et al.
Pageof 25

Showing results (171-180 of 244) with videos related to

Sort By:
Pageof 25
EJNMMI Research|March 17, 2025
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphomaMichael Beck, Viktoria Blumenberg, Veit L Bücklein, et al.
Clinical & Translational Immunology|March 11, 2020
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trialFelix S Lichtenegger, Frauke M Schnorfeil, Maurine Rothe, et al.
Hemasphere|April 11, 2023
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHLKai Rejeski, Viktoria Blumenberg, Gloria Iacoboni, et al.
Blood|February 26, 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyJoshua F Zeidner, David A Sallman, Christian Récher, et al.
Blood Advances|February 24, 2025
Gastrointestinal toxicity of Gemtuzumab Ozogamicin: Real-life data from the AMLCG, SAL and CELL study groupsRicarda Knabe, Philippe Muller, Christoph Schliemann, et al.
Transplantation|May 15, 2018
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsHeiner Zimmermann, Nina Babel, Daan Dierickx, et al.
Blood|July 25, 2022
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervalsNora Philipp, Maryam Kazerani, Alyssa Nicholls, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.
Leukemia|April 2, 2020
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemiaTobias Herold, Maja Rothenberg-Thurley, Victoria V Grunwald, et al.
Leukemia|August 2, 2024
Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemiaDaniel Atar, Lara Ruoff, Anna-Sophia Mast, et al.
Pageof 25